

---

## **BiBBInstruments AB: Publishes a letter from CEO Fredrik Lindblad**

**BiBBInstruments AB ("BiBB" or the "Company") publishes a letter from the CEO, Fredrik Lindblad, due to the beginning of the subscription period for warrants of series TO 1. The CEO letter is available on BiBB's website.**

In connection with the beginning of the subscription period for the warrants of series TO 1, the Company publishes a CEO letter. The CEO letter is available on BiBB's website:  
[www.bibbinstruments.com](http://www.bibbinstruments.com).

*This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.*

### **For more information about BiBB, please contact:**

Fredrik Lindblad, CEO  
E-mail: [fredrik.lindblad@bibbinstruments.com](mailto:fredrik.lindblad@bibbinstruments.com)  
Phone: +46 70 899 94 86  
[www.bibbinstruments.com](http://www.bibbinstruments.com)

---

### **About BiBB**

*BiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® – the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BiBB) is listed on Spotlight Stock Market.*

### **IMPORTANT INFORMATION**

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.